Monday, July 06, 2015 3:47:45 PM
Look for NNVC under "Infectious Diseases" section
http://www.iirusa.com/therapeuticareapartnership/presentingcos.xml
The 'Top Projects to Watch' are chosen to present in each therapeutic area, and are hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. Many presenting companies in previous years have gone on to establish major partnerships - Trius, Optimer, QRxPharma, Pearl Therapeutics, Vectura, AVEO, Trophos, and BiPar – just to name a few.
The criteria are:
- Large market, large unmet need, with increasing opportunity
- History of the molecule and drug
- Strong science
- Strong company
- Diversity of indications
- Potential for new opportunities beyond the initial indications
- Multi-level partnering opportunities, i.e., biotech to biotech
as well as pharma to biotech
All companies will present on November 20 and will be available for 1:1 partnering meetings during November 20-21.
Senior level business development and licensing executives from small to large pharmaceutical and biotechnology companies attend Therapeutic Area Partnerships every year.
Whether your goal is to introduce yourself to new customers or to enhance relationships with your current customers, you will have the opportunity to meet with decision-makers face-to-face to showcase your company before, during and after the event. Whatever your budget may be, sponsorship offers a great opportunity to reach the most senior level decision-makers.
We can discuss your goals and objectives and work to design the best sponsorship package for your needs. We will work with you throughout the event to enhance your ROI and to ensure you meet your goals. We have many different sponsorship opportunities that will allow you to show your commitment to the industry and increase your presence and networking opportunities.
Agenda: http://www.iirusa.com/therapeuticareapartnership/agenda.xml
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM